<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79000">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02002546</url>
  </required_header>
  <id_info>
    <org_study_id>IRB# 13-069</org_study_id>
    <nct_id>NCT02002546</nct_id>
  </id_info>
  <brief_title>Usefulness of a 2-hour Delta Troponin-I During the ED Identification and Exclusion of Acute Myocardial Infarction</brief_title>
  <official_title>Usefulness of a 2-hour Delta Troponin-I During the ED Identification and Exclusion of Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chattanooga-Hamilton County Hospital Authority</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chattanooga-Hamilton County Hospital Authority</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. In chest pain patients with suspected acute coronary syndrome, a 2-hr delta Troponin-I
           as measured by the i-STAT immunoassay reliably identifies and excludes an acute
           myocardial infarction.

        2. In chest pain patients with suspected acute coronary syndrome whose baseline troponin
           is above the 99th percentile but less than 0.2ng/ml, a 2hr delta Troponin-I as measured
           by the i-STAT immunoassay accurately discriminates between acute myocardial infarction
           and non-acute myocardial infarction troponin elevations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Aims: 1) Demonstrate that a 2hr delta troponin as measured by the i-STAT platform
      can reliably identify and exclude MI on the initial ED evaluation. 2)Demonstrate that a 2hr
      delta troponin is useful in the discrimination AMI versus non-AMI conditions in patients
      with low abnormal baseline Troponin-I values.

      Secondary Aims: 1) Demonstrate that a positive 2-hr delta troponin-I identifies patients at
      highest risk for 30 day ACE. 2) Other Secondary aims TBD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change in Troponin value over a two hour interval.</measure>
    <time_frame>2 hours after baseline</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>ED chest pain presenting patients</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients presenting to the Emergency Department with chest pain or similar symptoms,
        and risk factors for ACS.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients 18 years of age or older

          2. Chest pain suspicious for ACS

          3. Absence of ST-segment elevation AMI (STEMI) or STEMI equivalent on the initial ECG

          4. Baseline i-STAT troponin less or equal to 1.0 ng/ml

          5. Enrollment initiated before 2 hour 'delt' troponin value available for review

          6. Ability and willingness to participate and cooperate with telephone follow-up
             evaluations

        Exclusion Criteria:

          1. ST-elevation or other ECG criteria that results in the diagnosis of AMI and results
             in patient being sent for percutaneous coronary interventions (PCI) or being treated
             with thrombolytics

          2. Patients with chest pain not deemed to warrant cardiac screening

          3. Blunt chest trauma

          4. Tachyarrhythmia (ventricular tachycardia, supraventricular tachycardia, or rapid
             atrial fibrillation)

          5. Cardiac Arrest prior to arrival

          6. Hemodynamically unstable patients

          7. Pulmonary edema requiring CPAP, BIPAP, or mechanical ventilation

          8. Baseline i-STAT troponin measurement greater than 1.0 ng/ml

          9. Baseline and 2-hour i-STAT Troponin measurements not obtained

         10. Patient (or Legal Representative) unable or unwilling to provide written informed
             consent

         11. Subject unwilling or unlikely to comply with study procedures, including
             protocol-specific blood sampling

         12. Subject unwilling, unable, or deemed unlikely to respond or participate in telephone
             follow-up

         13. Vulnerable populations as deemed inappropriate for the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Donna J Carroll, Associate</last_name>
    <phone>423-778-3903</phone>
    <email>donna.carroll2@erlanger.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lakina Campbell, Master's</last_name>
    <phone>423-778-3902</phone>
    <email>lakina.campbell@erlanger.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erlanger Baroness Medical Center</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna J Carroll, Associates in Nursing</last_name>
      <phone>423-778-3903</phone>
      <email>donna.carroll2@erlanger.org</email>
    </contact>
    <contact_backup>
      <last_name>Lakina Campbell</last_name>
      <phone>423-778-3902</phone>
      <email>lakina.campbell@erlanger.org</email>
    </contact_backup>
    <investigator>
      <last_name>Harry W Severance, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ron C Buchheit, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert L Huang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sudave Mendiratta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 5, 2014</lastchanged_date>
  <firstreceived_date>December 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Attack</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Angina</keyword>
  <keyword>Chest Pain</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
